Abstract:Yuntao Lu, 1, 2, &ast Minyan Yin, 3, 4, &ast Ye Yang, 1, 2, &ast Wenshuo Wang, 1, 2 Lili Dong, 5 Xue Yang, 3, 4 Chunsheng Wang, 1, 2 Xiaolin Wang, 3, 4 Jinmiao Chen, 1, 2 Lai Wei 1, 2 1 Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China; 2 Shanghai Engineering Research Center of Heart Valve, Shanghai, People's Republic of China; 3 Shanghai Institute of Medical Imaging, Shanghai, People's Republic of China; 4 Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China; 5 Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lai Wei; Jinmiao Chen, Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China, Tel +86 021 64041990, Email ; Purpose: Transcatheter aortic valve replacement (TAVR) induced coronary artery obstruction (CAO) is a rare but devastating complication. Current preventive strategies need additional procedures and may be associated with adverse events. This study aimed to evaluate the early safety and efficacy of stand-alone TAVR using the J-Valve (Jianshi JieCheng Medical Technology Co. Ltd, Shanghai, China) in patients at potential high risk for CAO. Patients and Methods: CAO was defined as coronary ostia obstruction requiring intervention. Patients at potential high risk for CAO were identified retrospectively from 673 consecutive patients who underwent TAVR from January 2015 to July 2021 at Zhongshan Hospital, Fudan University. Procedural results and early outcomes were evaluated according to Valve Academic Research Consortium-3 definitions. Results: A total of 20 consecutive patients (age 72 ± 9 years; 85% female;) were included. The Society of Thoracic Surgeons-Predicted Risk of Mortality was 5% (interquartile range, 4 to 10%). All patients (100%) had at least 2 classical risk factors for CAO by pre-procedural computed tomography analysis, and 90% patients had native aortic valve diseases. TAVR was successful in 95% of cases, with only 1 patient requiring second device implantation. Early safety at 30 days was achieved in all cases without death. All patients were free from CAO, stroke or emergency reintervention. Post-procedural mean aortic valve gradient was 7 (interquartile range, 4, 12) mmHg, and none/trace or mild aortic regurgitation was present in all patients. Conclusion: Stand-alone TAVR using the J-Valve may mitigate the risk of TAVR-induced CAO. Keywords: TAVR, coronary artery obstruction, aortic regurgitation, aortic stenosis, structural heart disease Graphical Coronary artery obstruction (CAO) in transcatheter aortic valve replacement (TAVR) or transcatheter aortic valve-in-valve implantation (TAVIV) is caused by the displacement of the diseased leaflet (native valve or bioprostheses) toward the coronary ostia and/or sinotubular junction (STJ) by the implanted transcatheter heart valve (THV). It is a rare complication (incidence < 1% in TAVR, ≈3% in TAVIV); however, it is likely to be underestimated, as many patients are excluded from TAVR due to potential CAO risk. 1–3 TAVR-induced CAO is devastating because the 30-day mortality rate is 52.9%. 3 Risk factors for CAO during TAVR include but not limited to female, low-lying coronary ostia, narrow sinus of Valsalva, bioprostheses with externally mounted leaflets and stentless surgical valve. 1,3 Surgical aortic valve replacement is the standard treatment for patients at high risk of TAVR-induced CAO. Additional interventions may be useful, including coronary protection with pre-emptive wiring and stenting (regular stent and chimney technique) 4,5 and bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (BASILICA). 6,7 Although both techniques have the potential to prevent CAO in selected patients, they are also associated with the risk of serious complications, such as stent failure and stroke. 8 J-Valve (Jianshi JieCheng Medical Technology Co, Ltd, Shanghai, China) is a self-expanding, low-profile transapical heart valve. Previous studies have reported the feasibility of the J-Valve for treatment in aortic regurgitation and/or stenosis, and the mid-term outcomes were promising. 9–11 J-Valve was reported to use as a new opti -Abstract Truncated-

A novel anatomic classification to guide transcatheter aortic valve replacement for pure aortic regurgitation

Computed tomography anatomical characteristics based on transcatheter aortic valve replacement in aortic regurgitation

Can Measuring the 'Dual Anchors of Aorta' Enhance the Success Rate of TAVR?-A Single-Center Experience

Transcatheter Aortic Valve Replacement in Patients with Pure Native Aortic Regurgitation: Results from a Multicenter Registry Study

Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study

Evaluation of the safety and efficacy of a novel Anatomical classification and dUal anchoRing theory to Optimize the tavR strategy for pure severe Aortic regurgitation (AURORA): a prospective cohort study

Transapical Transcatheter Aortic Valve Replacement Under 3-Dimensional Guidance to Treat Pure Aortic Regurgitation in Patients with a Large Aortic Annulus

Transcatheter management of pure native aortic valve regurgitation in patients with Left-Ventricular assist device

Transapical aortic valve implantation using J-Valve? system for high-risk patients with aortic regurgitation: mid-stage of 1 year follow-up

Transapical Transcatheter Aortic Valve Implantation for Predominant Aortic Regurgitation with a Self-Expandable Valve

Transcatheter Aortic Valve Replacement for Bicuspid Vs. Tricuspid Aortic Stenosis among Patients at Low Surgical Risk in China: from the Multicenter National NTCVR Database

Transcatheter Aortic Valve Replacement for Pure Native Aortic Valve Regurgitation: A Systematic Review

Novel Apical-to-femoral Rail Technique for Horizontal Aorta in Transcatheter Aortic Valve Replacement

A study on correlation between preprocedural CT indexes and procedural success rate of transfemoral transcatheter aortic valve replacement with different self-expanding valves (VitaFlow or VenusA-Valve) in patients with pure native aortic regurgitation

[Value of Preoperative Assessment on Transcatheter Aortic Valve Implantation Procedure with High-Pitch Dual-Source Computed Tomography Angiography].

Abstract 15819: The Outcome of Transcatheter Aortic Valve Replacement for Pure Aortic Regurgitation: A Updated Systematic Review and Meta-Analysis

Single‐center experience with self‐expanding transcatheter aortic valve system for symptomatic high‐risk patients with severe aortic regurgitation: One‐year outcomes

Counterpoint: challenges and limitations of transcatheter aortic valve implantation for aortic regurgitation

A Coronary-Friendly Device Mitigating Risk of Coronary Obstruction in Transcatheter Aortic Valve Replacement

Long-Term Clinical Outcomes of Transcatheter Aortic Valve Replacement Using J-Valve System for Patients with Pure Native Aortic Regurgitation

Outcomes of transcatheter aortic valve replacement for pure native aortic regurgitation with the use of newer- vs. early-generation devices